Neurotech Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Rhode Island, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
900 Highland Corporate Dr Ste 101, Cumbe...Phone Number
(401) 333-3880Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Neurotech Pharmaceuticals
Neurotech Pharmaceuticals, Inc. is a private biotech company focused on developing transformative therapies for chronic eye diseases, specifically targeting Macular Telangiectasia (MacTel) Type 2. They offer MacTel treatment solutions, clinical trials, and their proprietary Encapsulated Cell Therapy (ECT) platform, which releases Ciliary Neurotrophic Factor (CNTF) to protect against photoreceptor loss. Their intended clients include healthcare professionals and patients suffering from MacTel, who experience gradual loss of central vision. The company is committed to advancing innovative treatments and has received FDA approval for their product ENCELTO.Explore more
Neurotech Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neurotech Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Neurotech Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Neurotech Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Neurotech Pharmaceuticals has new funding data
Earning: See what the market has to say on Neurotech Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Neurotech Pharmaceuticals
Product Launch: Get notified when Neurotech Pharmaceuticals launches new products
Neurotech Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Neurotech Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Neurotech Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Neurotech Pharmaceuticals
Compare insights from companies similar to Neurotech Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Neurotech Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neurotech Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neurotech Pharmaceuticals.
Neurotech Pharmaceuticals financials insights
Gather financial insights about Neurotech Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Series B
$15M
Neurotech Pharmaceuticals Tech Stack
A closer look at the technologies used by Neurotech Pharmaceuticals
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Neurotech Pharmaceuticals News & Media
Cencora to support US launch of Neurotech's cell therapy, ENCELTO
Neurotech partners with Cencora for the U.S. launch of ENCELTO, the first FDA-approved treatment for MacTel, enhancing patient access and support.Neurotech Appoints Beth Marsh as Chief Commercial Officer
CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Beth will lead the commercial organization, including preparing for the U.S. launch of ENCELTOTM (revakinagene taroretcel-lwey), the first and only approved treatment for adults with idiopathic Macular Telangiectasia Type 2Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel)
CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and Drug Administration (FDA), has approved ENCELTO™ (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel). MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients' qualityNeurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FDA), has extended the Prescription Drug User Fee Act (PDUFA) goal date by three months to allow time required for the FDA to review additional data provided by the Company in response to recent requests from the FDA. The new PDUFA goal date for the biologics license application (BLA) of NT-501
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neurotech Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Neurotech Pharmaceuticals, Inc. is a private biotech company focused on developing transformative therapies for chronic eye diseases, specifically targeting Macular Telangiectasia (MacTel) Type 2. They offer MacTel treatment solutions, clinical trials, and their proprietary Encapsulated Cell Therapy (ECT) platform, which releases Ciliary Neurotroph... Read More
